Diagnostic Imaging Pathways - Chronic Thromboembolic Pulmonary Hypertension (Suspected)
- Pathway Home
- Pathway
- Images
- Teaching Points
- cteph
- vq
- tte
- ct
- rhcatheter
- cathpa
- ctpa
- mr
- References
- Information for Consumers
- copyright
Pathway Home
Population Covered By The Guidance
This pathway provides guidance on the imaging of adult patients with suspected chronic thromboembolic pulmonary hypertension.
Date reviewed: November 2018
Date of next review: November 2021
Published: March 2019
Quick User Guide
Move the mouse cursor over the PINK text boxes inside the flow chart to bring up a pop up box with salient points.
Clicking on the PINK text box will bring up the full text.
The relative radiation level (RRL) of each imaging investigation is displayed in the pop up box.
SYMBOL | RRL | EFFECTIVE DOSE RANGE |
![]() | None | 0 |
![]() | Minimal | < 1 millisieverts |
![]() | Low | 1-5 mSv |
![]() | Medium | 5-10 mSv |
![]() | High | >10 mSv |
Teaching Points
Teaching Points
- A diagnosis of CTEPH was previously associated with a poor prognosis, however it is now potentially curable with surgery or balloon pulmonary angioplasty. Improvements in medical and endovascular treatments have led to some improved survival in inoperable or refractory CTEPH
- Lung scintigraphy (V/Q or ventilation/perfusion scan) is the first-imaging modality to investigate suspected CTEPH. A normal V/Q scan rules out a diagnosis of CTEPH with high certainty. CTEPH may still be present with an intermediate scan
- CT pulmonary angiography (CTPA) alone frequently misses the diagnosis of CTEPH so it is not recommended to rule it out
- Possible cases of CTEPH or pulmonary hypertension due to other causes should be referred to a specialist centre for further evaluation
- Transthoracic echocardiogram (TTE) may suggest pulmonary hypertension, but invasive measurement of right heart pressures and pulmonary artery wedge pressures with right heart catheterisation is required to confirm the diagnosis
- The role of CTPA or magnetic resonance pulmonary angiography (MRPA) and cardiac MRI is to assess disease severity, distribution and location to allow planning for surgery or radiological interventions and to assess right ventricular volume and function as a marker for treatment response. The chance of success with surgery is greatest when vascular obstruction is present in the main pulmonary arteries or lobar arteries. Balloon pulmonary angioplasty is successful at treating segmental and subsegmental arteries
- Catheter pulmonary angiography remains the gold standard for diagnosis and treatment work up and all patients require this to plan intervention
cteph
Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
- Chronic thromboembolic pulmonary hypertension (CTEPH) is classified as group 4 pulmonary hypertension
- CTEPH is a serious but rare adverse sequela of acute pulmonary embolism (PE) that occurs in about 3% of PE survivors, 1 although up to 38% of patients with CTEPH have no documented history of venous thromboembolism 2
- A diagnosis of CTEPH was previously associated with a poor prognosis, however it is now potentially curable with surgery. 3 Improvements in medical and endovascular treatments have led to some improved survival in inoperable or refractory CTEPH 3
- Diagnosing CTEPH following PE is challenging because symptoms are generally non-specific; diagnosis is delayed on average for by over a year 4
- Routine screening for CTEPH after PE is not currently recommended 5
- Unfortunately guidelines are lacking for how long patients should be followed up after PE and when diagnostic tests for CTEPH should be performed 6
- Patients with a higher burden of thrombus at time of diagnosis are at increased risk 7
- CTEPH can be suspected in patients who remain symptomatic after 3 months of effective anticoagulation. 5 Risk factors for developing CTEPH include recurrent PE and unprovoked PE 4
- CTEPH can also develop in the absence of previous diagnosed acute PE. 5 Patients with known clotting disorders and underlying connective tissue diseases such as scleroderma are at increased risk
- CTEPH is defined as: 8
- Mean pulmonary artery pressure ≥25mmHg
- Pulmonary capillary wedge pressure <15mmHg and
- Persistence of multiple organised thrombi in the lobar, segmental or sub-segmental pulmonary arteries after at least 3 months of effective anticoagulation
- CTEPH can also be a result of organised thrombus, e.g. vessel occlusion or stenosis. These can be present in the absence of residual thrombus
- However, not all patients with residual clot burden proceed to develop pulmonary hypertension and incidental clot may co-exist with other groups of pulmonary hypertension. Likewise, pulmonary hypertension may be multifactorial which would have implications for management, so early referral to a specialist centre is recommended in suspected pulmonary hypertension
- Sarcoid involving the pulmonary arteries mimics CTEPH and can only be identified following transplant or at autopsy. This can be suspected in patients with known sarcoidosis with symptoms and/or imaging features of CTEPH
vq
Lung Scintigraphy (V/Q or ventilation/perfusion scan)
- Lung scintigraphy (V/Q or ventilation/perfusion scan) is the first-imaging modality for CTEPH and can rule out a diagnosis of CTEPH with high certainty 5
- Originally found to have a significantly higher sensitivity than CTPA (96-97.4% compared to 51%) 9,10
- More recent studies with later CT technology have demonstrated comparable sensitivity for V/Q scan and CTPA for CTEPH, 11 so there may be a growing role for CTPA in the future
- Radiolabelled compounds are inhaled for ventilation scanning, whilst perfusion scintigraphy is performed after intravenous injection of technetium-99m macroaggregated albumin. A PE characteristically appears as a pleural based segmental perfusion defect 12
- Patients with CTEPH show at least one segmental or larger perfusion defect unmatched by ventilation abnormalities 13
- Visualisation of the vascular bed with CTPA or MRA (or DSA) is still required for treatment decision making following V/Q scan 5
- Ventilation perfusion scans, compared to CTPA, are associated with lower radiation exposure but the extreme difference between the effective doses as existed previously has been reduced drastically with the new generation MDCT helical scanners that use low dose (using tube currents of 80kVp or 100kVp) 14-18
tte
Transthoracic Echocardiogram
- In patients presenting with dyspnoea following treated PE, echocardiography is recommended as a first-line on-invasive diagnostic investigation for the assessment of pulmonary artery pressures 5,13
- TTE also gives information on the presence of structural cardiac abnormalities, valvular dysfunction and systolic or diastolic cardiac function that may contribute to symptoms. 13 Cardiac MRI is the gold standard for assessment of the right ventricle, however it is not widely available
- If TTE findings are compatible with a high or intermediate probability of pulmonary hypertension, a V/Q scan is recommended to exclude CTEPH. 5 However, a positive TTE is not required for diagnosis
- TTE alone is not sufficient to support a treatment decision or to rule out CTEPH in patients with risk factors. 5 If suspected, a V/Q scan should be performed irrespective of TTE
- TTE relies on tricuspid regurgitation of pulmonary arterial hypertension (PAH) and can miss diagnoses. For example, if right heart failure is present, TTE may not demonstrate tricuspid regurgitation despite elevated pulmonary arterial pressures, resulting in false negatives
- Alternatively, pulmonary artery pressures should still be confirmed with right heart catheter because TTE may over-diagnose pulmonary hypertension by up to three times 1
- In asymptomatic patients with a high risk of CTEPH, V/Q scan may be the diagnostic test of choice to rule out CTEPH 13
- Some patients have chronic thromboembolic pulmonary disease without PAH. These patients may warrant monitoring as they may develop PAH, although there have been no studies to demonstrate this 13
ct
Chest Computed Tomography (CT)
- Non-contrast CT chest can be useful in the work up of pulmonary hypertension to assess the lung parenchyma, which may reveal a cause for PAH or separate cause for symptoms. 5 Can also rule out extrinsic pulmonary vascular compression from other causes such as neoplasm or fibrosis 13
- Multislice CT (or multidetector CT, MDCT) can be reconstructed into thin slices to assess parenchymal and bronchial detail, and continuous thick slices to assess for small nodules. Multislice CT has a fast acquisition time and high resolution when reconstructed in different planes
rhcatheter
Right Heart Catheterisation
- Invasive assessment of pulmonary haemodynamics is still required to confirm the diagnosis and to evaluate operability, as TTE may over- or underestimate pulmonary artery pressures 5
- There is a low associated risk of adverse events, with 1.1% associated morbidity and 0.05% mortality 19
- Pulmonary hypertension is defined as mean pulmonary artery pressure ≥25mmHg and pulmonary capillary wedge pressure <15mmHg 8
- Symptomatic patients with imaging findings consistent with CTEPH but normal pressures may be considered to have chronic thromboembolic pulmonary vascular disease (CTED). These patients may warrant monitoring for the development of PAH, although the natural history of CTED is unknown and there have been no studies to show that CTED evolves into CTEPH 13
cathpa
Catheter Pulmonary Angiography (Digital Subtraction Angiography)
- Invasive investigation that demonstrates the extent and location of disease; indicated to assess whether CTEPH may be amenable to surgical treatment. Also allows for endovascular intervention
- The chance of success with surgery is greatest when vascular obstruction is present in the main pulmonary arteries or lobar arteries 20
- Balloon pulmonary angioplasty can be used to treat peripheral obstructions in segmental or subsegmental pulmonary branches, and can be undertaken in conjunction with medical therapy. There is growing evidence for BPA as a promising treatment for patients who are unsuitable for surgery 21-23
ctpa
CT Pulmonary Angiography (CTPA)
- May be useful to demonstrate evidence of acute or chronic thromboembolic disease in patients without known history of PE and an indeterminate V/Q scan
- Role of CTPA is well established for the diagnosis of acute PE
- However, CTPA is not recommended to rule out CTEPH due to the high rate of false negatives. CTPA has a significantly lower sensitivity than V/Q scan (51% compared to 96-97.4%) 9
- Signs of CTEPH on CTPA include direct vascular signs of chronic PE as well as secondary signs including:
- Eccentric, reorganised thrombus
- Webs in pulmonary arteries
- Pulmonary artery stenosis, which can be loss of normal tapering or focal overt stenosis. This is difficult to perceive via CT but is one of the commonest findings
- Pulmonary artery occlusions
- Paucity of distal vessels despite normal parenchyma. This is the cause for mosaic attenuation
- Dilated systemic collaterals
- Evidence of pulmonary hypertension, i.e. central pulmonary artery dilation, right heart dilation and right ventricular hypertrophy with flattening/bowing of the septum to the left, reflux of contrast into hepatic veins
mr
Magnetic Resonance Imaging: Pulmonary Angiography (MRPA or MRA), Pulmonary Perfusion and Cardiac MRI
- MRA is an excellent non-invasive test to whether CTEPH may be amenable to surgical or endovascular treatment
- MRA can demonstrate flow artefact caused by webs and stenoses which are not detectable on CT
- MR is also able to demonstrate perfusion deficits which correspond to abnormal vessels and defects seen on V/Q scan
- Cardiac MRI is the gold standard for the assessment of right ventricular function 24 and can also assess the myocardium and valve disease 18
- Gadolinium contrast-enhanced MRA has shown promise for the diagnosis of CTEPH with one study reporting sensitivity and specificity of 98 and 94% respectively 25
- MRI is especially useful as a baseline for follow-up and monitoring response to treatment 26
- Unlike CTPA and V/Q scan, there is no exposure to ionising radiation
- Disadvantages: 18
- Limited availability. MR can be misleading or non-diagnostic if not performed in a high-volume, experienced cardiothoracic imaging centre
- Cost
- Long acquisition time – dyspnoeic patients may not be able to achieve breath hold
- Claustrophobic
- Contraindicated with some ferromagnetic prostheses
References
References
References are graded from Level I to V according to the Oxford Centre for Evidence-Based Medicine, Levels of Evidence. Download the document
- Ende-Verhaar YM, Cannegieter SC, Vonk Noordegraaf A, Delcroix M, Pruszczyk P, Mairuhu AT, et al. Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature. Eur Respir J. 2017;49(2) (Level I evidence). View the reference
- Condliffe R, Kiely DG, Gibbs JS, Corris PA, Peacock AJ, Jenkins DP, et al. Prognostic and aetiological factors in chronic thromboembolic pulmonary hypertension. Eur Respir J. 2009;33(2):332-8. (Level III evidence). View the reference
- Delcroix M, Lang I, Pepke-Zaba J, Jansa P, D'Armini AM, Snijder R, et al. Long-term outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. Circulation. 2016;133(9):859-71. (Level II evidence). View the reference
- Pepke-Zaba J, Delcroix M, Lang I, Mayer E, Jansa P, Ambroz D, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation. 2011;124(18):1973-81. (Level II evidence). View the reference
- Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67-119. (Guideline). View the reference
- Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galie N, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014;35(43):3033-69, 69a-69k. (Guideline). View the reference
- Lang IM, Simonneau G, Pepke-Zaba JW, Mayer E, Ambroz D, Blanco I, et al. Factors associated with diagnosis and operability of chronic thromboembolic pulmonary hypertension. A case-control study. Thromb Haemost. 2013;110(1):83-91. (Level III evidence) View the reference
- Pengo V, Lensing AWA, Prins MH, Marchiori A, Davidson BL, Tiozzo F, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004;350(22):2257-64. (Level II evidence). View the reference
- Tunariu N, Gibbs SJ, Win Z, Gin-Sing W, Graham A, Gishen P, et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med. 2007;48(5):680-4. (Level II-III evidence). View the reference
- Worsley DF, Palevsky HI, Alavi A. Ventilation-perfusion lung scanning in the evaluation of pulmonary hypertension. J Nucl Med. 1994;35(5):793-6. (Level II-III evidence). View the reference
- Rajaram S, Swift AJ, Telfer A, Hurdman J, Marshall H, Lorenz E, et al. 3D contrast-enhanced lung perfusion MRI is an effective screening tool for chronic thromboembolic pulmonary hypertension: results from the ASPIRE Registry. Thorax. 2013;68(7):677-8. (Level II-III evidence). View the reference
- Donkers-van Rossum AB. Diagnostic strategies for suspected pulmonary embolism. The European respiratory journal. 2001;18(3):589-97. (Review article). View the reference
- Klok FA, Delcroix M, Bogaard HJ. Chronic thromboembolic pulmonary hypertension from the perspective of patients with pulmonary embolism. J Thromb Haemost. 2018 (Review article). View the reference
- Litmanovich D, Tack D, Lin PJ, Boiselle PM, Raptopoulos V, Bankier AA. Female breast, lung, and pelvic organ radiation from dose-reduced 64-MDCT thoracic examination protocols: a phantom study. AJR American journal of roentgenology. 2011;197(4):929-34. (Level III evidence). View the reference
- Szucs-Farkas Z, Schibler F, Cullmann J, Torrente JC, Patak MA, Raible S, et al. Diagnostic accuracy of pulmonary CT angiography at low tube voltage: intraindividual comparison of a normal-dose protocol at 120 kVp and a low-dose protocol at 80 kVp using reduced amount of contrast medium in a simulation study. AJR American journal of roentgenology. 2011;197(5):W852-9. (Level III evidence). View the reference
- Szucs-Farkas Z, Kurmann L, Strautz T, Patak MA, Vock P, Schindera ST. Patient exposure and image quality of low-dose pulmonary computed tomography angiography: comparison of 100- and 80-kVp protocols. Investigative radiology. 2008;43(12):871-6. (Level III evidence). View the reference
- Zamboni GA, Guariglia S, Bonfante A, Martino C, Cavedon C, Mucelli RP. Low voltage CTPA for patients with suspected pulmonary embolism. European journal of radiology. 2012;81(4):e580-4. (Level III evidence). View the reference
- Ruggiero A, Screaton NJ. Imaging of acute and chronic thromboembolic disease: state of the art. Clin Radiol. 2017;72(5):375-88. (Review article). View the reference
- Hoeper MM, Lee SH, Voswinckel R, Palazzini M, Jais X, Marinelli A, et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol. 2006;48(12):2546-52. (Level II evidence). View the reference
- Jenkins D. Pulmonary endarterectomy: the potentially curative treatment for patients with chronic thromboembolic pulmonary hypertension. Eur Respir Rev. 2015;24(136):263-71. (Review article). View the reference
- Tanabe N, Kawakami T, Satoh T, Matsubara H, Nakanishi N, Ogino H, et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: A systematic review. Respiratory investigation. 2018;56(4):332-41. (Review article) View the reference
- Phan K, Jo HE, Xu J, Lau EM. Medical therapy versus balloon angioplasty for CTEPH: A systematic review and meta-analysis. Heart, lung & circulation. 2018;27(1):89-98. (Level I-II evidence) View the reference
- Tamada N, Nakayama K, Yanaka K, Onishi H, Shinkura Y, Tsuboi Y, et al. Early introduction of pulmonary endarterectomy or balloon pulmonary angioplasty contributes to better health-related quality of life in patients with chronic thromboembolic pulmonary hypertension. JACC Cardiovasc Interv. 2018;11(11):1114-6. (Level III evidence) View the reference
- Gopalan D, Delcroix M, Held M. Diagnosis of chronic thromboembolic pulmonary hypertension. Eur Respir Rev. 2017;26(143). (Review article) View the reference
- Rajaram S, Swift AJ, Capener D, Telfer A, Davies C, Hill C, et al. Diagnostic accuracy of contrast-enhanced MR angiography and unenhanced proton MR imaging compared with CT pulmonary angiography in chronic thromboembolic pulmonary hypertension. Eur Radiol. 2012;22(2):310-7. (Level II-III evidence). View the reference
- Berman M, Gopalan D, Sharples L, Screaton N, Maccan C, Sheares K, et al. Right ventricular reverse remodeling after pulmonary endarterectomy: magnetic resonance imaging and clinical and right heart catheterization assessment. Pulmonary Circulation. 2014;4(1):36-44. (Level III evidence) View the reference
Information for Consumers
Information for Consumers
Information from this website |
Information from the Royal Australian and New Zealand College of Radiologists’ website |
Consent to Procedure or Treatment Radiation Risks of X-rays and Scans Computed Tomography (CT) Angiography |
Iodine-Containing Contrast Medium Radiation Risk of Medical Imaging During Pregnancy Radiation Risk of Medical Imaging for Adults and Children Contrast Medium (Gadolinium versus Iodine) Magnetic Resonance Imaging (MRI) |
copyright
Copyright
© Copyright 2015, Department of Health Western Australia. All Rights Reserved. This web site and its content has been prepared by The Department of Health, Western Australia. The information contained on this web site is protected by copyright.
Legal Notice
Please remember that this leaflet is intended as general information only. It is not definitive and The Department of Health, Western Australia can not accept any legal liability arising from its use. The information is kept as up to date and accurate as possible, but please be warned that it is always subject to change
.File Formats
Some documents for download on this website are in a Portable Document Format (PDF). To read these files you might need to download Adobe Acrobat Reader.